*NEW* RECIST 1.1 Tumour Measurement Worksheet *NEW* RECIST 1.1 Tumour Measurement Worksheet A RECIST 1.1 Tumour Measurement Form has been created and is available to. Recist 1 1 Worksheet Template. The worksheet is an assortment of 4 intriguing pursuits that will enhance your kid's knowledge and abilities. The worksheets are offered in developmentally appropriate versions for kids of different ages. Adding and subtracting integers worksheets in many ranges including a number of choices for parentheses use
RECIST 1.1 - iRECIST template. Disclaimer. The primary intent of the RECIST website is to communicate efforts being made to refine response evaluation criteria and also the development of new evaluation criteria that can be used for targeted agents and with imaging technologies. The content of this website is the property of the RECIST. Summary: RECIST 1.1 ! RECIST 1.1: Know better than PI or Radiologist ! Measurement (Measureable, Non-Measureable, Target, Non-Target, and LN) ! # of lesions and # per organ (5/2) ! Work with Radiologist and PI to accurately document which lesion is being followed and from baseline or best response ! When is patient SD, PR, PRO
RECIST 1.1 Guidelines RECIST 1.1 Guidelines Measurable Tumor Burden A maximum of 10 target lesions in total (and u pt o5 er rgan) ca nbe i de tifie at baseline and measured through the course of therapy. A maximum of 5 target lesions in total (and up to 2 per org an) c n be identified t baseline and measured through the course of therapy Response Evaluation Criteria in Solid Tumors (RECIST) Quick Reference: Eligibility. Only patients with measurable disease at baseline should be included in protocols where objective tumor response is the primary endpoint. Measurable disease - the presence of at least one measurable lesion. If the measurable disease is restricted to a solitary. RECIST 1.1 Quick Reference. Subject Eligibility Only patients with measurable disease at baseline should be included in protocols where objective tumor response is the primary endpoint. Measurable disease is defined as the presence of at least one measurable lesion
Recist 1.1 is not used for lymphoma, GIST during Glivec therapy, HCC and malignant brain tumors. Other criteria have been published for these tumors. In addition a brief overview is given of variations of RECIST and some other response systems. Introduction. Baseline Study - five easy steps. 1. Is the study eligible for RECIST Per RECIST 1.1, in exceptional circumstances, unequivocal progression in non-target disease may result in RECIST 1.1 PD / iRECIST iUPD. Any increase in non-target tumour burden at the next assessment would allow iCPD to be confirmed; the increase does NOT have to be unequivocal (per RECIST 1.1) again. The same is true for new lesions Using RECIST 1.1 Criteria Definitions Tumor burden is composed of the sum of diameters of target lesions. Target Lesion / Non Target Lesion • Target Lesion is measured in only one dimension • The longest diameter of a target lesion must be >=10mm • Any lesion <10mm is called non targe
RECIST 1.1 - Adapting and updating guidelines to improve the assessment of outcomes. By pruyskart June 24, 2016. Hear Larry Schwartz summarize the latest work from the RECIST Working Group. One focuses on clarifying the interpretation of RECIST 1.1, and one provides a summary of current widely accepted alternatives to RECIST in certain. -Based on RECIST/RECIST 1.1 Wolchok JD, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res . 2009;15:7412-20
RECIST 1.1. Measurable Disease at BL. Required, MTLS. When required then MTLS, Pats. with non-measurable disease only are allowed. Minimum Target Lesion Size. ≥10 mm (Spiral CT) ≥20 mm (Conventional CT, MRI) ≥10 mm (CT + MRI) ≥15 mm Lymph nodes 1.3. Process of RECIST 1.1 development The RECIST Working Group, consisting of clinicians with expertise in early drug development from academic research organisations, government and industry, together with imag-ing specialists and statisticians, has met regularly to set the agenda for an update to RECIST, determine the evidenc Recist 1.1 calculator worksheet xls Keyword Found Keyword-suggest-tool.com DA: 28 PA: 44 MOZ Rank: 73 Features of the RECIST 1.1 calculator version 1.0 beta: Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable diease when the change is > -30% and ≤ 20%, partial response when there is a decrease RECIST 1.1: Definitions provided for. Norma l: short axis < 10 mm. Measurable (Target): short axis ≥ 15 mm. Non-measurable: short axis 10 to < 15 mm. Target nodes measured in the short axis (perpendicular to longest diameter) More reproducible and predictive of malignancy. Short axes of target nodes to be added to the sum of longest diameters RECIST stands for Response Evaluation Criteria in Solid Tumors. The National Cancer Institute is the best resource for information, and defines RECIST criter..
RECIST 1.0: No absolute increase in size required RECIST 1.1: Target Lesions: > 20% increase in the SLD taking as reference the smallest SLD recorded since the treatment started (nadir) and minimum 5 mm increase over the nadi This review aims to give a brief update how to do RECIST 1.1, irRECIST 1.1, and mRECIST. The revised Response Evaluation Criteria in Solid Tumors (RECIST 1.1) are currently representing the most commonly used and validated response criteria for objective treatment monitoring of conventional chemotherapies in solid tumors. However, with the introduction of novel molecular drugs and local tumor. RECIST 1.1, published in January 2009, is an update to the original criteria. Today, the majority of clinical trials evaluating cancer treatments for objective response in solid tumors are using RECIST. Cancer trials are increasingly complex, involving dozens or even hundreds of investigators from centers around the world
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis J Clin Oncol. 2019 May 1;37(13):1102-1110. doi: 10.1200/JCO.18.01100. Epub 2019 Mar 12. Authors Saskia Litière 1. Updated in 2008 (version 1.1) for further clarification, simplification and standardization . RECIST v1.1 Criteria! The purpose of RECIST guidelines is to standardize response assessment ! Most trials assessing response utilize RECIST ! Understanding RECIST criteria is critical to trial conduct and interpretation of results. •Choose)the)largestlesions)which)can)be)reproducibly) measured)(clear)margins))) •Windows: •Lung)lesionsFmeasure)on)LUNG)windows,)3.75)or) 5mm)thick) •All. Administration (FDA) and the RECIST group for feedback. We fully recognise that this is a work in progress and that the criteria are subject to revision on the basis of new data. Proposed RANO-BM criteria Similar to RECIST 1.1, deﬁ nitions for radiographical res ponse will be based on unidimensional measurements. Deﬁ nition
Import your excel file(xls, xlsx) Upload an excel file with a single sheet. (.xls & .xlsx files only, click this to download example file. * Column name should be [Patient ID (ID number must be consecutive with no gap), Organ (solid organ or lymph node), Lesion size at baseline (mm; zero or positive integer), Lesion size at post-treatment (mm; zero or positive integer)] RECIST terminology In order to clearly understand RECIST criteria before applying it in the clinical trials, it is important to understand some relevant terminologies. In RECIST criteria, lesion is generally used instead of tumor. The following terminologies are based on the revised RECIST guideline (version 1.1) RECIST 1.1 Lymph Node Assessment • Measure SHORT axis (not long axis) -> 15 mm: target lesion status -10 to <15 mm: non-target -< 10 mm: normal RECIST 1.1 training Perceptive Informatics, Inc Currently, RECIST 1.1 is the most used solid tumour assessment criteria in oncology clinical trials since it provide standardization, and the published rules and criteria are well established provide a framework for reproducible analysis and reporting of changes in tumour size. The set of rules that defined when cancer patients improv RECIST 1.1 to support the determination of a complete response (iCR) or of progressive disease (iPD), but meta-bolic response classification is not conducted . Baseline evaluation The baseline examination is supposed to be done as close to the start of immunotherapy as possible; in mos
Not everyone loves Recist 1.1 Advances in oncological treatment:limitations of RECIST 1.1 criteria Grimaldi S, et al. 2018 Recist 1.1 Reduced # of target lesions (max 5, 2 per organ) Revised assessment of lymph nodes Clarified the role of other imaging modalities Designed to evaluate tumor response to cytoxic therapies (mostly phase II trials modiﬁed RECIST assessment (mRECIST). Further studies are needed to conﬁrm the accuracy of this measurement compared with conventional gold standards such as pathologic studies of explanted livers. KEYWORDS: Hepatocellular carcinoma, RECIST, response assessment, time to progression magnetic resonance, computed tomography, AASLD-JNCI guidelines
A Clinical trial worksheet using RECIST v1.1 criteria.B Target lesion 1, right upper lobe nodule, C Target lesion 2, segment 2 liver mass, D Target lesion 3, segment 3 liver mass, E Non-target lesion 1, segment 6 liver masses. Target lesions are assessed by summing the diameters at baseline and follow-up time points. In this case, the shrinkage of target lesions results in a partial response. Download PAREXEL RECIST 1.1 for iOS to learn about RECIST 1.1 and how it can be applied to your clinical trial.RECIST (Response Evaluation Criteria In Solid Tumors) is a set of published.. Worksheet over two worksheets Recist 1 1 Addition of worksheet by Cpctc Worksheet, source:cathhsli.org Unit 113 Test theorems involving parallel lines and perp WITH ANSWERS!.notebook 3 October 04, 2017 Oct 3-1:08 note: You cannot use the... test worksheet of geometry name 3 date
Response evaluation criteria in solid tumors or RECIST refers to a set of published rules used to assess tumor burden in order to provide an objective assessment of response to therapy. They were initially introduced in 2000 and have undergone subsequent revision in 2009 ( RECIST 1.1 ). For the evaluation of tumors treated with immunotherapy. 18 best Relapse Prevention images on Pinterest from Addiction Recovery Worksheets, source:pinterest.com. Worksheet To Too Two Worksheet Recist 1 1 Worksheet Addiction from Addiction Recovery Worksheets, source:cathhsli.org. Smart Recovery Worksheets Free Worksheets Library from Addiction Recovery Worksheets, source:comprar-en-internet.net RECIST 1.1 Guidelines RECIST 1.1 Guidelines Measurable Tumor Burden A maximum of 10 target lesions in total (and u pt o5 er rgan) ca nbe i de tifie at baseline and measured through the course of therapy; A maximum of 5 target lesions in total (and up to 2 per org an) c n be identified t baseline and measured through the course of therapy Since RECIST was published in 2000, many investigators, cooperative groups, industry and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions and issues have arisen which have led to the development of a revised RECIST guideline (version 1.1)
RECIST 1.1 deals with mainly technical differences in scans that give the appearance that new lesions might have developed, or the concept of the isodense lesion at baseline that becomes more visible after the start of therapy since it becomes internally more necrotic as opposed to a true new lesion. However, the intention was never to use. RECIST 1.1 has its shortcomings for targeted immunotherapy in oncology. Using RECIST 1.1 in immunotherapy trials would lead to declaration of progressive disease (PD) too early, when the treatment effect is not yet fully evident. RECIST also neglects the importance of the 'flare effect' - pseudo-progression effect within the so-calle RECIST 1.1 criteria. The percent change of baseline for RECIST is generally calculated as: ((VALUE2 / VALUE1) - 1) * 100 = % CHANGE In this example, VALUE1 is representative of the current Nadir, and the VALUE2 represents the current SLD. This calculation will be like the calculation applied in Section 3, percent change from baseline 1 1. Surgery for low grade 1p/19q co-deleted OD Sept 2014 1st seizure November 2014 resection, wait and see March 2015: new enhance-ment: PD? T2 T1. T1C. ADC • 49 year old male, treated for glioblastoma • Recurrence in July 2012 • Gross total re-resection August 2, 201
Dr. Alicia Morgans (Northwestern University Feinberg School of Medicine) welcomes PCCTC Medical Director Dr. Michael Morris (Memorial Sloan Kettering Cancer Center) and Dr. Lawrence Schwartz (Columbia University Medical Center, New York-Presbyterian Hospital) to discuss the Prostate Cancer Working Group (PCWG3) criteria as a refresher for investigators who are treating men with prostate cancer. metric criteria and 54.3% according to RECIST. The CNS-speciﬁcprogression-freesurvivalwas7.3months,eventhough 54.3% of patients had an Eastern Cooperative Oncology Group performance status of 2 or 3 before treatment. On the basis of these data, further study of this concept is warranted. Lu et al . CHICAGO, IL USA (UroToday.com) - Dr. Howard Scher of Memorial Sloan Kettering presented the Prostate Cancer Working Group 3 (PCWG3) Consensus Guidelines, an update from the previously published Prostate Cancer Working Group 2 (PCWG2) set published in 2008 Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD: New Response Evaluation Criteria in Solid Tumors (revised RECIST guideline, version 1.1) in Advanced Non-Small-Cell Lung Cancer: Comparison with the original RECIST (version 1.0) and its impact on assessment of tumor response to therapy 97 FDA-Approved Oncology Drugs. With 30+ years' experience, supporting more than 1260 oncology drug studies across a wide range of indications, Bioclinica is the clear choice for an imaging partner for all phases of clinical oncology trials. We harness the power of leading experts and the most advanced imaging technology to streamline your.
Duration of administration Until radiographic progression by RECIST 1.1 or PCWG3 criteria Reference therapy N/A Statistical Methodology Bayesian phase 2 per Tighiouart . IIT2016-16-POSADAS-TRC105 Protocol Version 1 dated 24AUG 2017 4 STUDY SCHEMA . IIT2016-16-POSADAS-TRC10 All downloads are in PDF Format and consist of a worksheet and answer sheet to check your results. Ad Download over 30000 K-8 worksheets covering math reading social studies and more. Please get in touch if you want to contribute resources to share with your fellow teachers. Grammatical concepts both from a descriptive and a theoretical point.
Distance displacement online worksheet for Grade 4. The following shows a displacement of 5 m -7 -5 -4 -3 -1-6 -2 0 2135467 Meters fx i fx i. Distance and Displacement Worksheet Name_____ For each question plot the path on the grid paper. Distance and displacement worksheet pdf Toronto, Canada Area. •Participated in the coordination of clinical trials from protocol review and approval. •Monitored and promoted the quality and integrity of data, recorded clinical trial data in case report forms (CRF's), and compilation of ethics and regulatory documents. •The coordination and monitoring of data is performed in. RECIST v1.1 Tumor Assessment Worksheet Protocol: _____ Subject ID: _____ TARGET LESIONS: Exam/Scan Date → Baseline Procedure/Method→ Lesion Description↓ LD or SA in mm LD or SA in mm LD or SA in mm LD or SA in mm LD or SA in mm LD or SA in mm LD or SA in mm LD or SA in mm Present or Absent Present or Absent Present or Absent Present or Absent Present or Absent Present or Absent Present. Recist Calculator. Showing top 8 worksheets in the category - Recist Calculator. Some of the worksheets displayed are Recist applying the rules, Recist guidelines recist guidelines, The lugano classification, New response evaluation criteria in solid tumours revised, Response assessment criteria for brain metastases, Imaging response criteria training for pcwg modified recist 1, Parallel lines.
Based on the probabilities derived from the simulation, we developed an algorithm to evaluate the reliability of an ORR (or progression rate) (i.e., the variation in the assessed rate) by generating a 95% central range of ORR (or progression rate) results if a reassessment was performed. Finally, we performed validation using an external dataset Evaluation Criteria in Solid Tumors (RECIST) version 1.1, in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast For Cycle 5, the worksheet (source) documented Lesion #1 with a measurement of 17.1 mm, Lesion #2 with measurement of 15 mm, an Sample RECIST worksheet Name: Baseline Restaging#1 Restaging#2 Restaging#3 Restaging#4 Restaging#5 Resaging#6 Restaging#7 Date of Imaging 4/13/2012 6/1/2012 7/13/2012 8/24/2012 10/5/2012 11/16/2012 12/28/2012 Imaging Modality CT/MRI CT CT CT CT CT CT CT Target Lesion Site Target Lesion # Left Flank #1 1 12.70 12.70 13.00 13.70 17.80 13.90 13.6 Advertisement. New criteria for evaluating response in lymphoma clinical trials—RECIL 2017—have been developed by an International Working Group with the aim of harmonizing criteria with the Response Evaluation Criteria in Solid Tumors (RECIST). The new criteria were reported by Younes et al in Annals of Oncology The RECIST 1.1 and iRECIST guidelines provide various definitions, rules, and practical recommendations for a standardized solid tumor assessment in oncologic clinical trials , . First, two radiologists generated the conformity checklist as conditional statements according to the RECIST 1.1 and iRECIST rules and recommendations. The examples of.
2.1.1 Demographics Tab Field / Question Instructions SURGERY DATE 1. Date of Surgery Enter the date of the surgery using an 8-digit format with the month, day and 4-digit year. Use leading zeros before single digit months and days. For example: April 2nd, 2011, is entered as 04/02/2011 Target group criteria. A target audience is a group of people who have the same or similar needs.It is usually described on the basis of demographic and socio-economic characteristics, for example unmarried women aged 25 to 40 with a high income Target group specification is derived from defined research goals, i.e. specification of who we want to interview according to whose responses most.
DV-066 : Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies Xiangchen (Bob) Cui, Alkermes, Inc Sri Pavan Vemuri, Alkermes The objective tumor response rates (ORR) is one of endpoints in solid tumor clinical studies per FDA guideline  study or new lesions of new lesions as per RECIST 1.1 criteria. Overall survival was defined as the interval be-tween the first dose of dabrafenib and death due to any cause, end of study period or lost to follow up. The phase 1 study, BRF112680- A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate th .1. Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. The phrase responses to Hi, I have created an excel worksheet that has a certain table (including formats) copied and pasted 25 times to represent 25 time points within an experiment. Each row in a particular table (15 rows total) represents the status of a tumor over the 25 successive time points. I have used data validation in columns A and B to create a drop-down list that describes the location and status of a. This free resistor calculator converts the ohm value and tolerance based on resistor color codes and determines the resistances of resistors in either parallel or series, as well as the resistance of a conductor. Experiment with the voltage drop and Ohm's Law calculators, or explore hundreds of other calculators
patients who according to RECIST 1.1 and GCIC criteria had obtained at least a partial response after the completion of adjuvant chemotherapy were considered first line ther-apy responders (responders), while those with a stable or progressive disease where categorized as non-responders. Statistical analyse Training internal team and site teams on protocol, therapeutic area, RECIST 1.1, applicable study & regulatory requirements Show more Show less Clinical Team Leader Boehringer Ingelheim Oct 2012 - Mar 2017 4 years 6 months. Mumbai Area, India Managed Metastatic Colo-rectal Cancer and Moderate to severe Asthma trials as Associate Project Manager. In the protocol amendment, RECIST 1.1 was also added as a method for assessing CNS tumor response . The evaluation of the extra-CNS tumor using contrast-enhanced CT images was conducted every 3 months, and its response was evaluated according to RECIST 1.1 . Neurologic examinations were conducted within 1 day of each BEEP cycle • Response based on both local and central assessments using RECIST 1.1 for the following endpoints: EQ5D-3L questionnaires) will be analyzed. Detailed costs collected using data in eCRF, hospital invoices and pharmacy worksheet data will also be used as information for pharmacoeconomy analyses. as from 1.1.2021, EU Law applies only.
Logon. This Web site is live; any form submissions or registrations must be real. Login with your CTEP-IAM credentials Interventions Patients were randomized 1:1 to enzalutamide 160 mg or placebo until confirmed radiographic disease progression or a skeletal-related event and A separate investigator assessment of imaging was performed at each site using a bone scan worksheet adapted from the Prostate Cancer revised RECIST guideline (version 1.1) The Tumor Imaging Metrics Core (TIMC) provides standardized, consistent, longitudinal, multimodality radiological measurements to evaluate therapeutic response for patients enrolled in DF/HCC clinical trials. Visit our website. Contact Information. Tumor Imaging Metrics Core. 25 New Chardon Street Suite 501. Boston, MA 02114. Phone: 617-643-7813 Industry pioneers in adaptive clinical trials, offering clinical trial software and data analysis solutions to support the full drug development journey>>
The Percentage Change Calculator (% change calculator) will quantify the change from one number to another and express the change as an increase or decrease. This is a % change calculator. From 10 apples to 20 apples is a 100% increase (change) in the number of apples. This calculator will be most commonly used when there is an old and. Patient benefit was defined by the absence of central nervous system (CNS) disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in addition to no tumour-related worsening of the neurological signs and symptoms (NSS), no tumour-related increase in corticosteroid dosage and no progression of extra CNS disease according to RECIST 1.1 The randomised. 9.1.1. Deficiencies in the maintaining study records are escalated to the Phase I Director and, if applicable, a member of SC Clinical Operations for resolution. 9.1.2. Unresolved deficiencies are escalated to the PI and/or Sponsor to determine the Research Shadow Chart RECIST Worksheet or other tumor specific response shee
Sponsor: APGD ISN/Protocol 9785 -CL-0222 - CONFIDENTIAL - 10 Aug 2010 Astellas Page 1 of 81 A Randomized, Double-Blind, Phase II, Efficacy and Safet Microsoft Edge needs additional information to securely display your Office 365 content
The resulting multimedia radiology report includes measurements of targeted lesions along with automated RECIST 1.1 calculations, presented in tables and graphs that show changes in lesion size over time. Example of a multimedia radiology report for three metastatic (urothelial cancer) target lesions that have been followed over a year and show. - overall response rate formula - Similar to the above, Figure 5 is shown based on the example data. based on objective response rate (ORR), determined by tumor assessments from radiological tests or physical examinations. Rate: a ratio of count per observation time; often expressed as count per standard unit of time (e.g., per minute, per hour, per day) and calculated by dividing the number.
(RECIST) version 1.123 that allowed the selec-tion of up to five target lesions in the brain. MRI of the brain was performed every 6 weeks through cycle 6, then every 9weeks. Response was meas - ured by one central radiology reviewer. Clinical neurological assessments using a Neurological Signs and Symptoms (NSS) worksheet were don •Developed advanced knowledge of oncology disease-sites, staging and pathology reports through the review of eligibility criteria, completion of RECIST 1.1 and iRECIST assessments, documenting immune-mediated adverse events, etc The extra-CNS ORR was evaluated using RECIST version 1.1. 23 Safety and tolerability were assessed at each study visit according to the NIH-NCI CTCAE version 4.03. Statistical analysis The primary endpoint was a 12-week CNS ORR Entrustable Professional Activity Worksheet a Abbreviations: MK, Medical Knowledge; PC, Patient Care; ICS, Interpersonal and Communication Skills; P, Professionalism; PBLI, Practice-Based Learning and Improvement; SBP, Systems-Based Practice; RECIST, Response Evaluation Criteria in Solid Tumors; ASCO, American Society of Clinical Oncology; NCCN.
Analyze solid tumors according to the PCWG- Modified RECIST 1.1 criteria Show more Show less Indiana University-School of Informatics and Computing Capstone Project IU School of Informatics and. RECIST 1.1-Update and clarification: From the RECIST committee. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS. To achieve this, it is necessary to evaluate the blood smear, the immunophenotype, and, in some cases, the genetic features of the circulating lymphoid cells (see sections 1.1, 1.2, and 1.3). Blood The diagnosis of CLL requires the presence of ≥5 × 10 9 /L B lymphocytes in the peripheral blood, sustained for at least 3 months Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Genetic/Familial High-Risk Assessment: Colorectal Lung Cancer Screening. Prostate Cancer Early Detection. Adult Cancer Pain Antiemesis Cancer-Associated Venous Thromboembolic Disease Cancer-Related Fatigue. Distress Management Hematopoietic Cell Transplantation Hematopoietic. Bristol-Myers Squibb. Jun 2017 - Jan 20191 year 8 months. Lawrenceville, New Jersey. - Drive timely execution and operational management of clinical research studies. - Central team operational. Accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research